(Source: PRNewswire)
NEW YORK, July 6 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that Eamonn P. Hobbs, 51, a member of the Delcath Board of Directors since October 2008, has been appointed President and CEO of the Company. Mr. Hobbs succeeds Richard Taney who has led the company since December 2006 and will continue to serve on the Company's Board of Directors.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )
Mr. Hobbs has over 25 years of experience in the interventional radiology, interventional cardiology and gastroenterology medical device industries. From 1988 until earlier this year, Mr. Hobbs was President and CEO of AngioDynamics, Inc. (Nasdaq: ANGO). As a co- founder, he built AngioDynamics into a leading medical technology company with an international market presence and a highly diverse product line. Throughout his tenure at AngioDynamics, Mr. Hobbs led the Company's efforts in marketing, strategic planning, product development, and general management. In 2004, AngioDynamics was spun off from E-Z-EM, Inc., a healthcare company focused on diagnostic technologies, where Mr. Hobbs served as Senior Vice- President since 1988.
Before his involvement with these companies, Mr. Hobbs was the Director of Marketing and Product Development at NAMIC, Founder, President and CEO of Hobbs Medical, Inc., and a Product Development Engineer at Cook Incorporated. He received a Bachelor of Science in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts in 1980. In addition, Mr. Hobbs was elected to and currently serves on the Board of Directors of the Society of Interventional Radiology Foundation and as Vice Chairman of the Medical Device Manufacturers Association.
Commenting on his new position at Delcath, Mr. Hobbs stated, "I am delighted to be leading Delcath during this exciting time in our development. Richard has done an exceptional job leading the Company over the past two-plus years and I look forward to building on recent achievements. The promise of our drug delivery platform and its unique position in the interventional oncology space offers the opportunity to address a large and growing unmet medical need. I look forward to completing our Phase III clinical trials and submitting for FDA approval in a timely manner.
